Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci

被引:4
|
作者
Frosi, Y. [1 ]
Inoue, K. [2 ]
Ramlan, Siti Radhiah [1 ]
Lane, D. P. [1 ]
Watanabe, T. [2 ]
Brown, C. J. [1 ]
机构
[1] ASTAR, p53 Lab, Neuros Immunos, 8A Biomed Grove,06-04-05, Singapore 138648, Singapore
[2] Med & Biol Labs Co Ltd, R&D Div, 1063-103 Terasawaoka, Ina, Nagano 3960002, Japan
关键词
IN-VIVO; MDM2; INHIBITOR; P53; PATHWAY; ACTIVATION; PEPTIDES; CANCER; REACTIVATION; DISCOVERY; POTENT;
D O I
10.1038/s41598-019-54123-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this report we describe the development of a Fluorescent Protein-Protein Interaction-visualization (FLUOPPI) to enable the simultaneous measurement of both Mdm2:p53 and Mdm4:p53 interactions in order to assess the relative efficiencies of mimetic molecules of the p53 peptide helix against both PPIs. Mdm2 and Mdm4 overexpression frequently leads to the inactivation of non-mutated p53 in human cancers, via inhibition of its transcriptional activity, enhancing its degradation by the proteasome or by preventing its nuclear import. Development of inhibitors to disrupt the binding of one or both of these protein interactions have been the subject of intensive pharmaceutical development for anti-cancer therapies. Using the bimodal FLUOPPI system we have characterised compounds that were either monospecific for Mdm2 or bispecific for both Mdm2 and Mdm4. We have also demonstrated that the FLUOPPI assay can reliably differentiate between specific and non-specific disruption of these protein complexes via accurate assessment and normalization to the cell population under measurement. We envision that this methodology will increase the efficiency of identifying compounds that are either specific against a single PPI from a closely related family of interactions or compounds that interact across multiple related PPI pairs, depending on which is more desirable.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci
    Y. Frosi
    K. Inoue
    Siti Radhiah Ramlan
    D. P. Lane
    T. Watanabe
    C. J. Brown
    [J]. Scientific Reports, 9
  • [2] DISRUPTION OF P53/MDM2/MDMX PROTEIN-PROTEIN INTERACTIONS
    Topper, M.
    Zhou, M.
    Anderson, L.
    McLaughlin, M.
    [J]. BIOPOLYMERS, 2009, 92 (04) : 332 - 332
  • [3] Targeting protein-protein interactions: Lessons from p53/MDM2
    Murray, Justin K.
    Gellman, Samuel H.
    [J]. BIOPOLYMERS, 2007, 88 (05) : 657 - 686
  • [4] Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability
    Pant, Vinod
    Xiong, Shunbin
    Iwakuma, Tomoo
    Quintas-Cardama, Alfonso
    Lozano, Guillermina
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (29) : 11995 - 12000
  • [5] Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4
    Fan, Chuandong
    Wang, Xinjiang
    [J]. CELL CYCLE, 2017, 16 (07) : 660 - 664
  • [6] Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
    Grinkevich, Vera V.
    Vema, Aparna
    Fawkner, Karin
    Issaeva, Natalia
    Andreotti, Virginia
    Dickinson, Eleanor R.
    Hedstrom, Elisabeth
    Spinnler, Clemens
    Inga, Alberto
    Larsson, Lars-Gunnar
    Karlen, Anders
    Wilhelm, Margareta
    Barran, Perdita E.
    Okorokov, Andrei L.
    Selivanova, Galina
    Zawacka-Pankau, Joanna E.
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [7] Selective and dual action p53/mdm2/mdm4 antagonists
    Wang, Kan
    Doemling, Alexander
    [J]. CANCER RESEARCH, 2009, 69
  • [8] MDM2 and MDM4: p53 regulators as targets in anticancer therapy
    Toledo, Franck
    Wahl, Geoffrey M.
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (7-8): : 1476 - 1482
  • [9] Mdm2 and Mdm4 loss regulates distinct p53 activities
    Barboza, Juan A.
    Iwakuma, Tomoo
    Terzian, Tamara
    El-Naggar, Adel K.
    Lozano, Guillermina
    [J]. MOLECULAR CANCER RESEARCH, 2008, 6 (06) : 947 - 954
  • [10] Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions
    Zhang, Shiyan
    Lou, Jianfeng
    Li, Yafang
    Zhou, Feilong
    Yan, Ziqin
    Lyu, Xilin
    Zhao, Yujun
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 10621 - 10640